Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through its proprietary Phospholipid Drug Conjugate™ platform. This centralized news resource provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time information about CLRB’s radiopharmaceutical pipeline, including lead candidate iopofosine I 131 for hematologic malignancies and emerging programs targeting solid tumors. Our news collection covers critical updates ranging from trial results to manufacturing advancements, all curated to support informed decision-making.
Key content areas include clinical trial progress, FDA designations, scientific presentations, and corporate collaborations. The platform serves as a reliable source for tracking the company’s mission to improve cancer treatment precision through its novel drug delivery technology.
Bookmark this page for continuous access to verified updates about Cellectar’s innovative oncology programs. Check regularly for new developments in targeted radiopharmaceuticals and PDC platform applications across therapeutic areas.
On September 15, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced that CEO James Caruso will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 12:25 PM ET. The presentation will provide a company overview, highlighting its focus on developing targeted cancer therapies using its proprietary Phospholipid Drug Conjugate™ platform. Cellectar is currently conducting a pivotal Phase 2 study for its lead candidate, iopofosine, aimed at providing targeted delivery of iodine-131 for cancer treatment.
Cellectar Biosciences (NASDAQ: CLRB) announced a significant achievement on August 18, 2021, securing a $2 million Phase II NIH Small Business Innovation Research grant from the National Cancer Institute. This funding will bolster the ongoing pivotal study of iopofosine I-131 in treating Waldenstrom’s macroglobulinemia, which began in January 2021 and aims for full enrollment within 18 months. With over $46.8 million in cash equivalents reported as of June 30, 2021, the company is projected to sustain operations into Q3 2023, covering top-line data and NDA submission.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has signed a commercial manufacturing and supply agreement with Evergreen Theragnostics to boost the production capabilities of iopofosine I-131. This partnership will enhance the supply for clinical studies, particularly for Waldenstrom’s macroglobulinemia, and future therapeutic programs. The USAN has designated 'iopofosine I-131' as the generic name for CLR-131. The collaborative effort aims to meet market demand in the U.S. and beyond, ensuring efficient distribution and production of this promising radiotherapeutic.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported its Q2 financial results for 2021, highlighting a net loss of $6.0 million, or $0.11 per share, compared to a $3.6 million loss in 2020. Cash and equivalents stood at $46.8 million. R&D expenses increased to $4.6 million due to costs related to a pivotal study for Waldenstrom’s macroglobulinemia. Positive data was presented on CLR 131, showing a 100% overall response rate in six patients. The company has announced two collaborations to expand its PDC therapeutics pipeline.
Cellectar Biosciences (NASDAQ: CLRB) has expanded its collaboration with IntoCell Inc. to further develop phospholipid drug conjugates (PDCs). This collaboration utilizes IntoCell's innovative OHPAS linker chemistry alongside Cellectar's phospholipid ethers to create new PDCs. The partnership has demonstrated sufficient preclinical success to proceed with IND-enabling studies. Cellectar retains rights to globally develop any resulting OHPAS-containing PDCs, enhancing its pipeline of targeted cancer therapies.
Cellectar Biosciences (NASDAQ: CLRB) has formed a collaboration with South Korea-based LegoChemBio for developing first-in-class phospholipid drug conjugates (PDCs). This partnership aims to leverage both companies' technologies to create new therapies targeting solid tumors with unmet medical needs. The agreement allows for joint development of three novel PDC candidates and offers options for global commercialization rights. Financial terms remain undisclosed. Both companies are optimistic about enriching their oncology pipelines and advancing cancer treatment.
Cellectar Biosciences, focused on cancer treatment, announced that President and CEO James Caruso will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 3:00 pm. The presentation will detail the company's drug development initiatives, including the CLR 131 treatment for Waldenstrom’s macroglobulinemia. A replay will be available on their website after the event. Cellectar utilizes its proprietary Phospholipid Drug Conjugate™ platform to create targeted cancer therapies, aiming for improved efficacy and safety.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced the election of Dr. Asher Alban Chanan-Khan to its board of directors as an independent director. Dr. Chanan-Khan brings extensive experience in oncology, notably in hematologic cancers, and will play a critical role in advancing the company's cancer-targeting assets, including CLR 131. The company continues to focus on developing drugs that leverage its Phospholipid Drug Conjugate™ platform, which aims for improved efficacy in cancer treatment.
Cellectar Biosciences, Inc. (CLRB) presented promising results at the ASCO Annual meeting regarding CLR 131, a treatment for relapsed/refractory B-cell hematologic cancers. The Phase 2 CLOVER-1 study revealed a 100% overall response rate in six patients with Waldenstrom's macroglobulinemia, including an 83.3% major response rate and a 16.7% complete response rate. Notably, mean treatment-free remission is 1.1 years, with progression-free survival not yet reached after 18 months for high-risk patients. The ongoing trial aims to enroll 50 WM patients and explore further efficacy and safety outcomes.
Cellectar Biosciences (NASDAQ: CLRB) has announced a virtual poster presentation at the ASCO Annual Meeting from June 4-8, 2021, detailing findings from its Phase 2a study of CLR 131 in Waldenstrom’s macroglobulinemia (WM). The presentation will highlight results from six patients. Management will host a KOL call with Dr. Sikandar Ailawadhi, the lead investigator, on June 4 at 10:00 am. CLR 131 targets cancer cells using the company’s Phospholipid Drug Conjugate (PDC) delivery platform and is part of a pivotal trial aimed at understanding treatment responses in WM patients.
